
Maribel Diaz-Ricart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7718045/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock, 2022, 57, 95-105.	2.1	43
2	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. Cardiovascular Drugs and Therapy, 2022, 36, 547-560.	2.6	37
3	The Interplay between Pathophysiological Pathways in Early-Onset Severe Preeclampsia Unveiled by Metabolomics. Life, 2022, 12, 86.	2.4	6
4	Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic. Transfusion, 2022, 62, 227-246.	1.6	14
5	An endothelial proinflammatory phenotype precedes the development of the engraftment syndrome after autologous Hct. Bone Marrow Transplantation, 2022, 57, 721-728.	2.4	2
6	Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy. American Journal of Obstetrics and Gynecology, 2022, 227, 277.e1-277.e16.	1.3	23
7	TMAO and Gut Microbial-Derived Metabolites TML and Î ³ BB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. Journal of Clinical Medicine, 2022, 11, 1425.	2.4	2
8	Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Frontiers in Medicine, 2022, 9, 811504.	2.6	11
9	MO241: Nets and Terminal Complement Pathway as Potential Biomarkers for Complement Overactivation Assessment in Anca-Associated Vasculitis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
10	Southeast Asian ovalocytosis detected in a critical patient with COVIDâ€19 pneumonia. International Journal of Laboratory Hematology, 2022, 44, .	1.3	1
11	Endothelial damage and dysfunction in acute graft-versus-host disease. Haematologica, 2021, 106, 2147-2160.	3.5	26
12	Complement as the enabler of carfilzomibâ€induced thrombotic microangiopathy. British Journal of Haematology, 2021, 193, 181-187.	2.5	20
13	Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia. Cardiovascular Drugs and Therapy, 2021, 35, 521-532.	2.6	15
14	Diagnostic challenges in von Willebrand disease. Report of two cases with emphasis on multimeric and molecular analysis. Platelets, 2021, 32, 697-700.	2.3	1
15	Multicentric evaluation of the new HemosIL Acustar [®] chemiluminescence ADAMTS13 activity assay. International Journal of Laboratory Hematology, 2021, 43, 485-493.	1.3	10
16	Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI). Transfusion and Apheresis Science, 2021, 60, 103011.	1.0	12
17	Role of fibrinogen concentrates for treatment of critical perioperative hemorrhage. Drugs of Today, 2021, 57, 219.	1.1	1
18	Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. Scientific Reports, 2021, 11, 3048.	3.3	25

#	Article	IF	CITATIONS
19	Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2021, 29, 57.	2.6	2
20	Progressive endothelial cell damage in correlation with sepsis severity. Defibrotide as a contender. Journal of Thrombosis and Haemostasis, 2021, 19, 1948-1958.	3.8	12
21	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. Expert Opinion on Therapeutic Targets, 2021, 25, 423-433.	3.4	6
22	Thrombotic microangiopathies assessment: mind the complement. CKJ: Clinical Kidney Journal, 2021, 14, 1055-1066.	2.9	14
23	P.149: Extracellular Vesicles From Patients With Diabetic Nephropathy Induce Endothelial Dysfunction Through ICAM-1 and VCAM-1 in an In Vitro Model. Transplantation, 2021, 105, S61-S61.	1.0	0
24	Internalization of microparticles by platelets is partially mediated by toll-like receptor 4 and enhances platelet thrombogenicity. Atherosclerosis, 2020, 294, 17-24.	0.8	16
25	Upâ€regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide. Journal of Cellular and Molecular Medicine, 2020, 24, 1713-1723.	3.6	18
26	Hyperhemolytic Transfusion Reaction in Non-Hemoglobinopathy Patients and Terminal Complement Pathway Activation: Case Series and Review of the Literature. Transfusion Medicine Reviews, 2020, 34, 172-177.	2.0	4
27	Response to Maccio et al, "Multifactorial pathogenesis of COVIDâ€19â€related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?â€r Journal of Thrombosis and Haemostasis, 2020, 18, 3111-3113.	3.8	10
28	The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. Bone Marrow Transplantation, 2020, 55, 2270-2278.	2.4	9
29	Defibrotide inhibits donor leucocyteâ€endothelial interactions and protects against acute graftâ€versusâ€host disease. Journal of Cellular and Molecular Medicine, 2020, 24, 8031-8044.	3.6	23
30	Endothelial Damage, Inflammation and Immunity in Chronic Kidney Disease. Toxins, 2020, 12, 361.	3.4	43
31	Platelet Dysfunction in Noonan and 22q11.2 Deletion Syndromes in Childhood. Thrombosis and Haemostasis, 2020, 120, 457-465.	3.4	4
32	Is sickle cell disease-related neurotoxicity a systemic endotheliopathy?. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 111-115.	0.9	1
33	Circulating Biomarkers of COVID-19-Triggered Endotheliopathy: From Conjecture to Certainty. Blood, 2020, 136, 31-32.	1.4	4
34	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS ONE, 2020, 15, e0241778.	2.5	5
35	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. Blood, 2020, 136, 6-8.	1.4	1
36	FO043ENDOTHELIAL DAMAGE IN CHRONIC KIDNEY DISEASE IS MEDIATED THROUGH HISTONE DEACETYLASE UPREGULATION AND CAN BE PREVENTED BY DEFIBROTIDE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0

#	Article	IF	CITATIONS
37	Complement Activation and Thrombotic Microangiopathies. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1719-1732.	4.5	57
38	Acute Graft-vsHost Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide. Frontiers in Immunology, 2019, 10, 2339.	4.8	31
39	Idarucizumab, but not procoagulant concentrates, fully restores dabigatranâ€altered platelet and fibrin components of hemostasis. Transfusion, 2019, 59, 2436-2445.	1.6	8
40	Lithium Augmentation Versus Citalopram Combination in Imipramine-Resistant Major Depression. Journal of Clinical Psychopharmacology, 2019, 39, 254-257.	1.4	6
41	Switching to Imipramine Versus Add-on Mirtazapine in Venlafaxine-Resistant Major Depression. Journal of Clinical Psychopharmacology, 2019, 39, 63-66.	1.4	9
42	Early Complications of Endothelial Origin. , 2019, , 315-322.		6
43	Endothelial Dysfunction in Hematopoietic Cell Transplantation. Clinical Hematology International, 2019, 1, 45.	1.7	19
44	Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1541-1547.	2.4	20
45	Translational evidence of prothrombotic and inflammatory endothelial damage in Cushing syndrome after remission. Clinical Endocrinology, 2018, 88, 415-424.	2.4	14
46	Antioxidant and Anti-Inflammatory Strategies Based on the Potentiation of Glutathione Peroxidase Activity Prevent Endothelial Dysfunction in Chronic Kidney Disease. Cellular Physiology and Biochemistry, 2018, 51, 1287-1300.	1.6	43
47	Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A. Drugs of Today, 2018, 54, 591.	1.1	0
48	Indoxyl sulfate, a uremic trigger for platelets. Blood, 2017, 129, 2599-2600.	1.4	3
49	Cell adhesive peptides functionalized on CoCr alloy stimulate endothelialization and prevent thrombogenesis and restenosis. Journal of Biomedical Materials Research - Part A, 2017, 105, 973-983.	4.0	18
50	Endothelial damage is aggravated in acute GvHD and could predict its development. Bone Marrow Transplantation, 2017, 52, 1317-1325.	2.4	52
51	Escitalopram Impairs Thrombin-Induced Platelet Response, Cytoskeletal Assembly and Activation of Associated Signalling Pathways. Thrombosis and Haemostasis, 2017, 117, 2312-2321.	3.4	8
52	Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation. PLoS ONE, 2017, 12, e0171486.	2.5	16
53	Andexanet alpha: A recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies. Drugs of Today, 2017, 53, 271.	1.1	4
54	Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness. Drugs of Today, 2017, 53, 423.	1.1	1

#	Article	IF	CITATIONS
55	In vitro evaluation of the hemostatic effectiveness of cryopreserved platelets. Transfusion, 2016, 56, 580-586.	1.6	42
56	What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. Blood, 2016, 127, 1719-1727.	1.4	59
57	Endothelial damage in major depression patients is modulated by SSRI treatment, as demonstrated by circulating biomarkers and an in vitro cell model. Translational Psychiatry, 2016, 6, e886-e886.	4.8	58
58	Internalization of Tissue Factor-Rich Microvesicles by Platelets Occurs Independently of GPIIb-IIIa, and Involves CD36 Receptor, Serotonin Transporter and Cytoskeletal Assembly. Journal of Cellular Biochemistry, 2016, 117, 448-457.	2.6	16
59	Reversal of Rivaroxaban-Induced Alterations on Hemostasis by Different Coagulation Factor Concentrates. Circulation Journal, 2015, 79, 331-338.	1.6	35
60	Role of sodium tungstate as a potential antiplatelet agent. Drug Design, Development and Therapy, 2015, 9, 2777.	4.3	7
61	<scp>TLR</scp> 4 and <scp>NALP</scp> 3 inflammasome in the development of endothelial dysfunction in uraemia. European Journal of Clinical Investigation, 2015, 45, 160-169.	3.4	58
62	Platelet reactivity assessment with VerifyNow®: Substitute or complement for light transmission aggregometry?. International Journal of Cardiology, 2015, 178, 221-222.	1.7	0
63	Mobilization of endothelial progenitor cells in acute cardiovascular events in the PROCELL study: Time-course after acute myocardial infarction and stroke. Journal of Molecular and Cellular Cardiology, 2015, 80, 146-155.	1.9	42
64	Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus. Lupus, 2015, 24, 1143-1149.	1.6	12
65	Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers. Transfusion Medicine Reviews, 2015, 29, 242-249.	2.0	26
66	Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1739-1745.	2.0	69
67	Automated preparation of whole blood–derived platelets suspended in two different platelet additive solutions and stored for 7 days. Transfusion, 2014, 54, 426-433.	1.6	6
68	The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 445-458.	3.3	6
69	Prothrombotic platelet phenotype in major depression: Downregulation by antidepressant treatment. Journal of Affective Disorders, 2014, 159, 39-45.	4.1	32
70	Idarucizumab Fully Restores Dabigatran-Induced Alterations on Platelet and Fibrin Deposition on Damaged Vessels: Studies in Vitro with Circulating Human Blood. Blood, 2014, 124, 2878-2878.	1.4	11
71	Vorapaxar for the reduction of atherothrombotic events. Drugs of Today, 2014, 50, 747.	1.1	0
72	Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 663-663.	1.4	0

#	Article	IF	CITATIONS
73	Evidence of Defibrotide Internalization and Its Protective Effect in a Hepatic Endothelial in Vitro model. Blood, 2014, 124, 5960-5960.	1.4	Ο
74	Quantitative and qualitative analysis of coagulation factors in cryoprecipitate prepared from freshâ€frozen plasma inactivated with amotosalen and ultraviolet A light. Transfusion, 2013, 53, 600-605.	1.6	18
75	Distinct Deleterious Effects of Cyclosporine and Tacrolimus and Combined Tacrolimus–Sirolimus on Endothelial Cells: Protective Effect of Defibrotide. Biology of Blood and Marrow Transplantation, 2013, 19, 1439-1445.	2.0	73
76	Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human Blood. PLoS ONE, 2013, 8, e78696.	2.5	126
77	Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates. Blood Transfusion, 2013, 11, 391-9.	0.4	36
78	mTOR inhibition and erythropoiesis: microcytosis or anaemia?. Nephrology Dialysis Transplantation, 2012, 27, 537-541.	0.7	33
79	Platelet-associated tissue factor enhances platelet reactivity and thrombin generation in experimental studies in vitro. Thrombosis Research, 2012, 130, e294-e300.	1.7	12
80	Reversal of the Antithrombotic Action of Rivaroxaban and Dabigatran: A Clinical Study in Healthy Volunteers Blood, 2012, 120, 2261-2261.	1.4	5
81	Coagulation Factor Concentrates Restore Alterations in Hemostasis Induced by a High Dose of Apixaban: Studies in Vitro with Circulating Human Blood Blood, 2012, 120, 2263-2263.	1.4	6
82	NFκB in the Development of Endothelial Activation and Damage in Uremia: An In Vitro Approach. PLoS ONE, 2012, 7, e43374.	2.5	35
83	Redistribution and Hemostatic Action of Recombinant Activated Factor VII Associated with Platelets. American Journal of Pathology, 2011, 178, 2938-2948.	3.8	24
84	Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 497-506.	2.0	66
85	Translational Research Efforts in Biomarkers and Biology of Early Transplant-Related Complications. Biology of Blood and Marrow Transplantation, 2011, 17, S101-S108.	2.0	5
86	Endothelin-1 levels predict endothelial progenitor cell mobilization after acute myocardial infarction. Microvascular Research, 2011, 82, 177-181.	2.5	16
87	Translational evidence of endothelial damage in obese individuals: inflammatory and prothrombotic responses. Journal of Thrombosis and Haemostasis, 2011, 9, 1236-1245.	3.8	40
88	The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplantation, 2011, 46, 1495-1502.	2.4	229
89	Reversion of the Experimental Hemodilutional Coagulopathy Induced by Crystalloids and Colloids Using Different Coagulation Factor Concentrates. Blood, 2011, 118, 4349-4349.	1.4	0
90	Impact of Different Immunosuppresive Drugs on the Endothelium. Protective Effect of Defibrotide. Blood, 2011, 118, 5319-5319.	1.4	3

#	Article	IF	CITATIONS
91	Tissue Factor Is Internalized by Platelets Through Activation of RhoA and PI3-Kinase Promoting Reversible Cytoskeletal Assembly,. Blood, 2011, 118, 3264-3264.	1.4	0
92	Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment. Psychoneuroendocrinology, 2010, 35, 481-489.	2.7	9
93	The secretory mechanisms in equine platelets are independent of cytoskeletal polymerization and occur through membrane fusion. Platelets, 2010, 21, 658-666.	2.3	2
94	Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen andAthe Type of Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 985-993.	2.0	109
95	Preanalytical treatment of EDTA-anticoagulated blood to ensure stabilization of the mean platelet volume and component measured with the ADVIA counters. Thrombosis Research, 2010, 126, e30-e35.	1.7	41
96	Serotonin enhances platelet procoagulant properties and their activation induced during platelet tissue factor uptake. Cardiovascular Research, 2009, 84, 309-316.	3.8	63
97	The Release of Soluble Factors Contributing to Endothelial Activation and Damage after Hematopoietic Stem Cell Transplantation Is Not Limited to the Allogeneic Setting and Involves Several Pathogenic Mechanisms. Biology of Blood and Marrow Transplantation, 2009, 15, 537-546.	2.0	66
98	Relative contributions of collagen and tissue factor to thrombus formation on damaged vascular vessels: in-vitro studies with circulating blood. Coronary Artery Disease, 2009, 20, 392-399.	0.7	5
99	Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thrombosis and Haemostasis, 2009, 102, 511-519.	3.4	62
100	Edoxaban tosilate. Drugs of the Future, 2009, 34, 861.	0.1	4
101	Neutrophil CD64 Is a Good Indicator of Infection and Sepsis Blood, 2009, 114, 1347-1347.	1.4	0
102	Differential Expression of Proteins From Cultured Endothelial Cells Exposed to Uremic Versus Normal Serum. American Journal of Kidney Diseases, 2008, 51, 603-612.	1.9	30
103	Inhibition of tyrosine kinase activity prevents the adhesive and cohesive properties of platelets and the expression of procoagulant activity in response to collagen. Thrombosis Research, 2008, 121, 873-883.	1.7	7
104	Internalization of tissue factor by platelets. Thrombosis Research, 2008, 122, S37-S41.	1.7	21
105	Apigenin Inhibits Platelet Adhesion and Thrombus Formation and Synergizes with Aspirin in the Suppression of the Arachidonic Acid Pathway. Journal of Agricultural and Food Chemistry, 2008, 56, 2970-2976.	5.2	74
106	External calcium facilitates signalling, contractile and secretory mechanisms induced after activation of platelets by collagen. Platelets, 2008, 19, 172-181.	2.3	3
107	Effects of etamsylate on equine platelets: In vitro and in vivo studies. Veterinary Journal, 2007, 174, 325-329.	1.7	9
108	Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. Thrombosis and Haemostasis, 2007, 97, 202-211.	3.4	30

#	Article	IF	CITATIONS
109	The Immunosuppressor Sirolimus Reduces the Number and Maturation of Colony-Forming Units of Erythroid Progenitor Cells Blood, 2007, 110, 3765-3765.	1.4	Ο
110	Endothelial Dysfunction in Autologous Hematopoietic Stem Cell Transplantation Blood, 2007, 110, 4855-4855.	1.4	0
111	Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. Thrombosis and Haemostasis, 2007, 97, 202-11.	3.4	7
112	Alterations of ADAMTS-13 Activity as a Common Indicator of the Endothelial Dysfunction Developing in Different Thrombotic Microangiopathies Blood, 2006, 108, 4091-4091.	1.4	0
113	Stabilization of the Mean Platelet Component (MPC), a Parameter Related to Platelet Granularity Provided by New Generation of Blood Analyzers Blood, 2006, 108, 3919-3919.	1.4	7
114	Efficient tyrosine phosphorylation of proteins after activation of platelets with thrombin depends on intact glycoprotein lb. Platelets, 2005, 16, 453-461.	2.3	5
115	Serotonergic mechanisms: A potential link between affective disorders and cardiovascular risk. Drugs of Today, 2005, 41, 721.	1.1	15
116	A Proteomic Approach to the Characterization of the Endothelial Dysfunction in Uremia Blood, 2005, 106, 3955-3955.	1.4	2
117	Comparative Evaluation of Hematologic Analyzers Advia® 120, Advia® 2120 and Pentra® 120DX for Platelet Counts below 40 X 109/L Blood, 2005, 106, 1256-1256.	1.4	Ο
118	Tissue Factor Enriched Microvesicles Plus Factor VIIa Induce Platelet Aggregation in the Absence of Coagulation Proteins: Evidence for the Involvement of Internalization and Trafficking Mechanisms Blood, 2005, 106, 1649-1649.	1.4	0
119	Uremic platelet dysfunction: past and present. Psychophysiology, 2005, 4, 359-67.	1.1	62
120	G-CSF increases the expression of VCAM-1 on stromal cells promoting the adhesion of CD34+ hematopoietic cells: studies under flow conditions. Experimental Hematology, 2004, 32, 765-772.	0.4	14
121	Decrease of the platelet 5-HT2A receptor function by long-term imipramine treatment in endogenous depression. Human Psychopharmacology, 2004, 19, 251-258.	1.5	23
122	Direct Activation of Platelets by Tissue Factor Is Amplified by FVIIa and Potentiated by Serotonin: Influence of Shear Rate Blood, 2004, 104, 3906-3906.	1.4	0
123	Granulocyte colony-stimulating factor increases expression of adhesion receptors on endothelial cells through activation of p38 MAPK. Haematologica, 2004, 89, 578-85.	3.5	45
124	Glycoproteins expression on platelet membrane in inherited macrothrombocytopenias. Thrombosis Research, 2003, 112, 233-237.	1.7	12
125	Uraemic medium accelerates proliferation but does not induce apoptosis of endothelial cells in culture. Nephrology Dialysis Transplantation, 2003, 18, 1079-1085.	0.7	26
126	Primary arrest of circulating platelets on collagen involves phosphorylation of Syk, cortactin and focal adhesion kinase: studies under flow conditions. Biochemical Journal, 2002, 364, 65-71.	3.7	10

#	Article	IF	CITATIONS
127	Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro. Thrombosis and Haemostasis, 2002, 88, 678-685.	3.4	84
128	TRAP Induces More Intense Tyrosine Phosphorylation than Thrombin with Differential Ultrastructural Features. American Journal of Pathology, 2002, 160, 2245-2252.	3.8	13
129	Inhibition of Cytoskeletal Assembly by Cytochalasin B Prevents Signaling Through Tyrosine Phosphorylation and Secretion Triggered by Collagen but Not by Thrombin. American Journal of Pathology, 2002, 160, 329-337.	3.8	15
130	Platelet 5-HT2A-receptor-mediated induction of aggregation is not altered in major depression. Human Psychopharmacology, 2002, 17, 419-424.	1.5	16
131	Phosphotyrosine proteins in platelets from patients with storage pool disease: direct relation between granule defects and defective signal transduction. Haematologica, 2002, 87, 629-36.	3.5	2
132	Erythropoietin does not modify the prothrombotic effect induced by uremic media on endothelial cells. Haematologica, 2002, 87, 1006-8.	3.5	5
133	Uremic medium causes expression, redistribution and shedding of adhesion molecules in cultured endothelial cells. Haematologica, 2002, 87, 1053-61.	3.5	43
134	Uremic Medium Disturbs the Hemostatic Balance of Cultured Human Endothelial Cells. Thrombosis and Haemostasis, 2001, 86, 1099-1105.	3.4	31
135	Uremic medium disturbs the hemostatic balance of cultured human endothelial cells. Thrombosis and Haemostasis, 2001, 86, 1099-105.	3.4	12
136	State-of-the-art knowledge on thrombosis and hemostasis. Drug News and Perspectives, 2001, 14, 508-12.	1.5	0
137	Abnormal platelet cytoskeletal assembly in hemodialyzed patients results in deficient tyrosine phosphorylation signaling. Kidney International, 2000, 57, 1905-1914.	5.2	27
138	Alterations in cytoskeletal organization and tyrosine phosphorylation in platelet concentrates prepared by the buffy coat method. Transfusion, 2000, 40, 535-542.	1.6	20
139	Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions. Haematologica, 2000, 85, 280-8.	3.5	12
140	New developments in thrombosis therapy. Drug News and Perspectives, 2000, 13, 363-5.	1.5	0
141	Erythropoietin Improves Signaling through Tyrosine Phosphorylation in Platelets from Uremic Patients. Thrombosis and Haemostasis, 1999, 82, 1312-1317.	3.4	43
142	Platelet concentrates prepared and stored under currently optimal conditions: minor impact on platelet adhesive and cohesive functions after storage. Transfusion, 1999, 39, 951-959.	1.6	38
143	Modifications in accessibility of membrane glycoproteins, binding of specific ligands and coagulation factor V during the activation of platelets in blood emerging from bleeding time wounds. , 1999, 60, 260-267.		3
144	Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thrombosis and Haemostasis, 1999, 82, 1312-7.	3.4	21

#	Article	IF	CITATIONS
145	Desmopressin (DDAVP) Enhances Platelet Adhesion to the Extracellular Matrix of Cultured Human Endothelial Cells through Increased Expression of Tissue Factor. Thrombosis and Haemostasis, 1997, 77, 0975-0980.	3.4	26
146	Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. Blood, 1996, 88, 2081-2092.	1.4	140
147	Antibodies to CD36 (GPIV) Inhibit Platelet Adhesion to Subendothelial Surfaces Under Flow Conditions. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 883-888.	2.4	16
148	Digital Image Analysis of Platelet-Extracellular Matrix Interactions: Studies in von Willebrand Disease Patients and Aspirin-Treated Donors. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1994, 24, 219-229.	0.3	7
149	Platelets lacking functional CD36 (glycoprotein IV) show reduced adhesion to collagen in flowing whole blood. Blood, 1993, 82, 491-496.	1.4	74
150	Platelets lacking functional CD36 (glycoprotein IV) show reduced adhesion to collagen in flowing whole blood. Blood, 1993, 82, 491-496.	1.4	1
151	Abnormal cytoskeletal assembly in platelets from uremic patients. American Journal of Pathology, 1993, 143, 823-31.	3.8	25
152	Platelets lacking functional CD36 (glycoprotein IV) show reduced adhesion to collagen in flowing whole blood. Blood, 1993, 82, 491-6.	1.4	6